Cognitive dysfunction in Huntington's disease: Humans, mouse models and molecular mechanisms

Journal of Huntington's Disease

Volumn 1, Issue 2, 2012, Pages 155-173

  Giralt, Albert ^a,b,c   Saavedra, Ana ^a,b,c   Alberch, Jordi ^a,b,c   Pérez Navarro, Esther ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

BDNF; CBP; hippocampus; LTD; LTP; PKA; striatum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTATIN; PHOSPHATASE; PHOSPHOTRANSFERASE; NERVE PROTEIN;

ASTROCYTE; BRAIN FUNCTION; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE MODEL; EXECUTIVE FUNCTION; FOREBRAIN; GENETIC TRANSCRIPTION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MOLECULAR MECHANICS; MOTOR DYSFUNCTION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SPATIAL LEARNING; STRATEGIC PLANNING; TEMPORAL CORTEX; ANIMAL; BIOLOGICAL MODEL; COGNITION; COGNITION DISORDERS; COMPLICATION; METABOLISM; NERVE CELL NETWORK; NERVE TRACT; PATHOPHYSIOLOGY; SPECIES DIFFERENCE; SYNAPTIC TRANSMISSION;

ANIMALS; COGNITION; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; MICE; MODELS, NEUROLOGICAL; NERVE NET; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; SPECIES SPECIFICITY; SYNAPTIC TRANSMISSION;

EID: 84880848685     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-120023     Document Type: Review

References (262)

1. Han I, You Y, Kordower JH, Brady ST, Morfini GA. Differential vulnerability of neurons in Huntington's disease: The role of cell type-specific features. J Neurochem. 2010;113(5):1073-91.
2. Gu X, Li C,Wei W, Lo V, Gong S, Li SH, et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron. 2005;46(3):433-44. (Pubitemid 40616887)
3. Gu X, Andre VM, Cepeda C, Li SH, Li XJ, Levine MS, et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener. 2007;2:8.
4. Nithianantharajah J, Hannan AJ. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience. 2012 (Epub ahead of print).
5. Li JY, Plomann M, Brundin P. Huntington's disease: A synaptopathy? Trends Mol Med. 2003;9(10):414-20. (Pubitemid 37309642)
6. Smith R, Brundin P, Li JY. Synaptic dysfunction in Huntington's disease: A new perspective. Cell Mol Life Sci. 2005;62(17):1901-12. (Pubitemid 41261838)
7. van DA, Grote HE, Hannan AJ. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin Exp Pharmacol Physiol. 2005;32(12):1007-19. (Pubitemid 43906809)
8. Lichter DG, Hershey LA. Before chorea: Pre-Huntington mild cognitive impairment. Neurology. 2010;75(6):490-1.
9. Paulsen JS. Cognitive impairment in Huntington disease: Diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474-83.
10. Trueman RC, Dunnett SB, Brooks SP. Operant-based instrumental learning for analysis of genetically modified models of Huntington's disease. Brain Res Bull. 2012;88(2-3):261-75.
11. Petrasch-Parwez E, Nguyen HP, Lobbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O, et al. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol. 2007;501(5):716-30.
12. Suopanki J, Gotz C, Lutsch G, Schiller J, Harjes P, Herrmann A, et al. Interaction of huntingtin fragments with brain membranes-clues to early dysfunction in Huntington's disease. J Neurochem. 2006;96(3):870-84.
13. Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci. 2006;31(1):21-9.
14. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998;121(Pt 7):1343-55. (Pubitemid 28327410)
15. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998;121(Pt 7):1329-41. (Pubitemid 28327409)
16. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J Neurol. 2004;251(8):935-42. (Pubitemid 39119311)
17. Snowden JS, Craufurd D, Thompson J, Neary D. Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol. 2002;24(2):133-45. (Pubitemid 34496862)
18. Giordani B, Berent S, Boivin MJ, Penney JB, Lehtinen S, Markel DS, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol. 1995;52(1):59-64.
19. Rothlind JC, Brandt J, Zee D, Codori AM, Folstein S. Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease. Arch Neurol. 1993;50(8):799-802. (Pubitemid 23229303)
20. Strauss ME, Brandt J. Is there increasedWAIS pattern variability in Huntington's disease? J Clin Exp Neuropsychol. 1985;7(1):122-6.
21. Hahn-Barma V, Deweer B, Durr A, Dode C, Feingold J, Pillon B, et al. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J Neurol Neurosurg Psychiatry. 1998;64(2):172-7. (Pubitemid 28159797)
22. Callicott JH, Weinberger DR. Neuropsychiatric dynamics: The study of mental illness using functional magnetic resonance imaging. Eur J Radiol. 1999;30(2):95-104. (Pubitemid 29281710)
23. Holler Y, Kronbichler M, Zeller A, Klein S, Hinterhuber H, Golaszewski S, et al. [Contribute of functional magnetic resonance imaging to the understanding of psychiatric disorders] . Neuropsychiatr. 2009;23(2):84-90.
24. Walter H, Berger M, Schnell K. Neuropsychotherapy: Conceptual, empirical and neuroethical issues. Eur Arch Psychiatry Clin Neurosci. 2009;259(Suppl 2):S173-82.
25. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta. 2009;1792(6):506-20.
26. Vonsattel JP. Huntington disease models and human neuropathology: Similarities and differences. Acta Neuropathol. 2008;115(1):55-69. (Pubitemid 50000780)
27. Wise SP, Murray EA. Role of the hippocampal system in conditional motor learning: Mapping antecedents to action. Hippocampus. 1999;9(2):101-17. (Pubitemid 29196955)
28. Giralt A, Rodrigo T, Martin ED, Gonzalez JR, Mila M, Cena V, et al. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipaseC gamma activity and glutamate receptor expression. Neuroscience. 2009;158(4):1234-50.
29. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 1999;19(23):10428-37. (Pubitemid 30228050)
30. McDonald RJ, Jones J, Richards B, Hong NS. A double dissociation of dorsal and ventral hippocampal function on a learning and memory task mediated by the dorso-lateral striatum. Eur J Neurosci. 2006;24(6):1789-801. (Pubitemid 44427548)
31. McDonald RJ, King AL,Wasiak TD, Zelinski EL, Hong NS. A complex associative structure formed in the mammalian brain during acquisition of a simple visual discrimination task: Dorsolateral striatum, amygdala, and hippocampus. Hippocampus. 2007;17(9):759-74. (Pubitemid 47493457)
32. Kandel ER, Pittenger C. The past, the future and the biology of memory storage. Philos Trans R Soc Lond B Biol Sci. 1999;354(1392):2027-52. (Pubitemid 30042041)
33. Thompson RF. In search of memory traces. Annu Rev Psychol. 2005;56:1-23. (Pubitemid 40300777)
34. Thompson RF, Kim JJ. Memory systems in the brain and localization of a memory. Proc Natl Acad Sci U S A. 1996;93(24):13438-44. (Pubitemid 26424139)
35. Gold PE. Coordination of multiple memory systems. Neurobiol Learn Mem. 2004;82(3):230-42. (Pubitemid 39298718)
36. Hartley T, Burgess N. Complementary memory systems: Competition, cooperation and compensation. Trends Neurosci. 2005;28(4):169-70. (Pubitemid 40445520)
37. White NM, McDonald RJ. Multiple parallel memory systems in the brain of the rat. Neurobiol Learn Mem. 2002;77(2):125-84. (Pubitemid 34971650)
38. Ghiglieri V, Sgobio C, Costa C, Picconi B, Calabresi P. Striatum-hippocampus balance: From physiological behavior to interneuronal pathology. Prog Neurobiol. 2011;94(2):102-14.
39. Rossato JI, Zinn CG, Furini C, Bevilaqua LR, Medina JH, Cammarota M, et al. A link between the hippocampal and the striatal memory systems of the brain. An Acad Bras Cienc. 2006;78(3):515-23. (Pubitemid 44371942)
40. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington's disease. Prog Neurobiol. 2007;81(5-6):253-71. (Pubitemid 46528639)
41. Bellotti R, De CF, Massafra R, de TM, Sciruicchio V. Topographic classification of EEG patterns in Huntington's disease. Neurol Clin Neurophysiol. 2004;2004:37.
42. Ehle AL, Stewart RM, Lellelid NA, Leventhal NA. Evoked potentials in Huntington's disease. A comparative and longitudinal study. Arch Neurol. 1984;41(4): 379-82. (Pubitemid 14167812)
43. Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: A morphometric MRI analysis. Cereb Cortex. 2005;15(6):846-53. (Pubitemid 40696123)
44. Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003;61(12): 1702-6. (Pubitemid 38020815)
45. Mink JW. The basal ganglia: Focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996;50(4):381-425. (Pubitemid 27028538)
46. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry. 1995;58(2):192-200.
47. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001;57(4):658-62. (Pubitemid 32782994)
48. Rosenberg NK, Sorensen SA, Christensen AL. Neuropsychological characteristics of Huntington's disease carriers: A double blind study. J Med Genet. 1995;32(8):600-4.
49. Schneider SA, Wilkinson L, Bhatia KP, Henley SM, Rothwell JC, Tabrizi SJ, et al. Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington's disease. Mov Disord. 2010;25(10):1343-9.
50. Lawrence AD, Sahakian BJ, Rogers RD, Hodge JR, Robbins TW. Discrimination, reversal, and shift learning in Huntington's disease: Mechanisms of impaired response selection. Neuropsychologia. 1999;37(12):1359-74. (Pubitemid 29440814)
51. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I. A prospective evaluation of cognitive decline in early Huntington's disease: Functional and radiographic correlates. Neurology. 1995;45(10):1867-73. (Pubitemid 27122960)
52. Heindel WC, Butters N, Salmon DP. Impaired learning of a motor skill in patients with Huntington's disease. Behav Neurosci. 1988;102(1):141-7.
53. Watkins LH, Rogers RD, Lawrence AD, Sahakian BJ, Rosser AE, Robbins TW. Impaired planning but intact decision making in early Huntington's disease: Implications for specific fronto-striatal pathology. Neuropsychologia. 2000;38(8):1112-25. (Pubitemid 30323662)
54. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(Pt 12):2207-17. (Pubitemid 28014597)
55. Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45(5):951-6.
56. Zakzanis KK. The subcortical dementia of Huntington's disease. J Clin Exp Neuropsychol. 1998;20(4):565-78. (Pubitemid 29030419)
57. Kim JS, Reading SA, Brashers-Krug T, Calhoun VD, Ross CA, Pearlson GD. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res. 2004;131(1):23-30. (Pubitemid 38891791)
58. Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy:Aneuropsychological and voxel-based morphometric study. J Neurol Sci. 2005;239(1):11-9. (Pubitemid 41617410)
59. Wolf RC, Vasic N, Schonfeldt-Lecuona C, Ecker D, Landwehrmeyer GB. Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp. 2009;30(1):327-39.
60. Hasselbalch SG, Oberg G, Sorensen SA, Andersen AR, Waldemar G, Schmidt JF, et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry. 1992;55(11):1018-23.
61. Kessels RP, de Haan EH, Kappelle LJ, Postma A. Varieties of human spatial memory: A meta-analysis on the effects of hippocampal lesions. Brain Res Brain Res Rev. 2001;35(3):295-303. (Pubitemid 32566202)
62. Clarke JR, Cammarota M, Gruart A, Izquierdo I, Delgado-Garcia JM. Plastic modifications induced by object recognition memory processing. Proc Natl Acad Sci U S A. 2010;107(6):2652-7.
63. Montaldi D, Mayes AR. The role of recollection and familiarity in the functional differentiation of the medial temporal lobes. Hippocampus. 2010;20(11):1291-314.
64. Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron. 2002;35(4):625-41. (Pubitemid 35223024)
65. Eichenbaum H. Hippocampus: Cognitive processes and neural representations that underlie declarative memory. Neuron. 2004;44(1):109-20. (Pubitemid 39348834)
66. Gruart A, Delgado-Garcia JM. Activity-dependent changes of the hippocampal CA3-CA1 synapse during the acquisition of associative learning in conscious mice. Genes Brain Behav. 2007;6(Suppl 1):24-31. (Pubitemid 46744108)
67. Berrios GE, Wagle AC, Markova IS, Wagle SA, Rosser A, Hodges JR. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: A comparison with gene negative at risk subjects. Acta Psychiatr Scand. 2002;105(3):224-30. (Pubitemid 34280696)
68. Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW. Visual object and visuospatial cognition in Huntington's disease: Implications for information processing in corticostriatal circuits. Brain. 2000;123(Pt 7):1349-64. (Pubitemid 30420936)
69. Montoya A, Pelletier M, Menear M, Duplessis E, Richer F, Lepage M. Episodic memory impairment in Huntington's disease: A meta-analysis. Neuropsychologia. 2006;44(10): 1984-94. (Pubitemid 43927985)
70. Voermans NC, Petersson KM, Daudey L, Weber B, Van Spaendonck KP, Kremer HP, et al. Interaction between the human hippocampus and the caudate nucleus during route recognition. Neuron. 2004;43(3):427-35. (Pubitemid 39061133)
71. Rosazza C, Minati L, Ghielmetti F, Maccagnano E, Erbetta A,Villani F, et al. Engagement of the medial temporal lobe in verbal and nonverbal memory: Assessment with functional MR imaging in healthy subjects. AJNR Am J Neuroradiol. 2009;30(6):1134-41.
72. Rohrer D, Salmon DP,Wixted JT, Paulsen JS. The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory. Neuropsychology. 1999;13(3): 381-8. (Pubitemid 29382609)
73. Wilson RS, Como PG, Garron DC, Klawans HL, Barr A, Klawans D. Memory failure in Huntington's disease. J Clin Exp Neuropsychol. 1987;9(2):147-54. (Pubitemid 17034464)
74. Butters N. The clinical aspects of memory disorders: Contributions from experimental studies of amnesia and dementia. J Clin Neuropsychol. 1984;6(1):17-36. (Pubitemid 14168928)
75. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990;113(Pt 5):1405-23. (Pubitemid 20385921)
76. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: A PET study. Brain. 2003;126(Pt 5):1127-35. (Pubitemid 36522955)
77. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice:Auser's guide. Nat Rev Neurosci. 2009;10(7):519-29.
78. Dunnett SB, Meldrum A, Muir JL. Frontal-striatal disconnection disrupts cognitive performance of the frontal-type in the rat. Neuroscience. 2005;135(4):1055-65. (Pubitemid 41416669)
79. Fukabori R, Okada K, Nishizawa K, Kai N, Kobayashi K, Uchigashima M, et al. Striatal direct pathway modulates response time in execution of visual discrimination. Eur J Neurosci. 2012;35(5):784-97.
80. Trueman RC, Brooks SP, Jones L, Dunnett SB. Rule learning, visuospatial function and motor performance in the Hdh(Q92) knock-in mouse model of Huntington's disease. Behav Brain Res. 2009;203(2):215-22.
81. Mazarakis NK, Cybulska-Klosowicz A, Grote H, Pang T, van DA, Kossut M, et al. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J Neurosci. 2005;25(12):3059-66. (Pubitemid 40463540)
82. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci. 2005;25(16):4169-80. (Pubitemid 40563393)
83. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319(6056):774-6. (Pubitemid 16145031)
84. Aggleton JP, Blindt HS, Rawlins JN. Effects of amygdaloid and amygdaloid-hippocampal lesions on object recognition and spatial working memory in rats. Behav Neurosci. 1989;103(5):962-74. (Pubitemid 19274528)
85. Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav Brain Res. 1998;95(1):91-101. (Pubitemid 28400375)
86. Broadbent NJ, Squire LR, Clark RE. Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci U S A. 2004;101(40):14515-20. (Pubitemid 39346780)
87. Brooks S, Higgs G, Janghra N, Jones L, Dunnett SB. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice. Brain Res Bull. 2012;88(2-3):113-20.
88. Giralt A, Saavedra A, Carreton O, Xifro X, Alberch J, Perez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: Role in Huntington's disease. Hum Mol Genet. 2011;20(21):4232-47.
89. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: Behavioral testing and impact of diabetes mellitus. Behav Brain Res. 2001;126(1-2):185-95. (Pubitemid 33009421)
90. Nithianantharajah J, Barkus C, Murphy M, Hannan AJ. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis. 2008;29(3):490-504.
91. Giralt A, Puigdellivol M, Carreton O, Paoletti P, Valero J, Parra-Damas A, et al. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet. 2012;21(6):1203-16.
92. Grote HE, Bull ND, Howard ML, van DA, Blakemore C, Bartlett PF, et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci. 2005;22(8):2081-8. (Pubitemid 41579396)
93. Smith R, Chung H, Rundquist S, Maat-Schieman ML, Colgan L, Englund E, et al. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet. 2006;15(21):3119-31. (Pubitemid 44605494)
94. Trueman RC, Brooks SP, Jones L, Dunnett SB. Time course of choice reaction time deficits in the Hdh(Q92) knock-in mouse model of Huntington's disease in the operant serial implicit learning task (SILT). Behav Brain Res. 2008;189(2):317-24.
95. Trueman RC, Jones L, Dunnett SB, Brooks SP. Early onset deficits on the delayed alternation task in the Hdh(Q92) knock-in mouse model of Huntington's disease. Brain Res Bull. 2012;88(2-3):156-62.
96. Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience. 2010;170(1):324-36.
97. Ciamei A, Morton AJ. Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. Neurobiol Learn Mem. 2008;89(4):533-44.
98. Ciamei A, Morton AJ. Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntington's disease. Neurobiol Learn Mem. 2009;92(3):417-28.
99. Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361(6407):31-9. (Pubitemid 23020772)
100. Akhondzadeh S. Hippocampal synaptic plasticity and cognition. J Clin Pharm Ther. 1999;24(4):241-8. (Pubitemid 29403317)
101. Bennett MR. The concept of long term potentiation of transmission at synapses. Prog Neurobiol. 2000;60(2):109-37.
102. Milnerwood AJ, Raymond LA. Early synaptic pathophysiology in neurodegeneration: Insights from Huntington's disease. Trends Neurosci. 2010;33(11):513-23.
103. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, et al. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res. 2001;5;66(4):525-39. (Pubitemid 33032321)
104. Plotkin JL, Wu N, Chesselet MF, Levine MS. Functional and molecular development of striatal fast-spikingGABAergic interneurons and their cortical inputs. Eur J Neurosci. 2005;22(5):1097-108. (Pubitemid 41395373)
105. Rebec GV, Conroy SK, Barton SJ. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: Variations with behavioral state and repeated ascorbate treatment. Neuroscience. 2006;137(1):327-36. (Pubitemid 43031499)
106. Starling AJ, Andre VM, Cepeda C, de LM, Chandler SH, Levine MS. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res. 2005;82(3):377-86. (Pubitemid 41552488)
107. Milnerwood AJ, Raymond LA. Corticostriatal synaptic function in mouse models of Huntington's disease: Early effects of huntingtin repeat length and protein load. J Physiol. 2007;585(Pt 3):817-31.
108. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci. 2001;21(23):9112-23. (Pubitemid 33096854)
109. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res. 1999;58(4):515-32. (Pubitemid 29530435)
110. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33(6):849-60. (Pubitemid 34246352)
111. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y,Wu NP, et al. Differential susceptibility to excitotoxic stress inYAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci. 2009;29(7):2193-204.
112. Cybulska-Klosowicz A, Mazarakis NK, van DA, Blakemore C, Hannan AJ, Kossut M. Impaired learning-dependent cortical plasticity in Huntington's disease transgenic mice. Neurobiol Dis. 2004;17(3):427-34. (Pubitemid 39574876)
113. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayai SC, et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet. 2006;15(19):2856-68. (Pubitemid 44446806)
114. Cummings DM, Milnerwood AJ, Dallerac GM, Vatsavayai SC, Hirst MC,MurphyKP. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease. Brain Res Bull. 2007;72(2-3):103-7. (Pubitemid 46367455)
115. Dallerac GM, Vatsavayai SC, Cummings DM, Milnerwood AJ, Peddie CJ, Evans KA, et al. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: Rescue by D1 dopamine receptor activation. Neurodegener Dis. 2011;8(4):230-9.
116. Kung VW, Hassam R, Morton AJ, Jones S. Dopaminedependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience. 2007;146(4):1571-80. (Pubitemid 46783231)
117. Giralt A, Carreton O, Lao-Peregrin C, Martin ED, Alberch J. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol Neurodegener. 2011;6(1):71.
118. Di Filippo M, Tozzi A, Picconi B, Ghiglieri V, Calabresi P. Plastic abnormalities in experimental Huntington's disease. Curr Opin Pharmacol. 2007;7(1):106-11. (Pubitemid 46238035)
119. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol. 2001;86(6):2667-77. (Pubitemid 33139038)
120. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, et al. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001;169(2):340-50. (Pubitemid 32524428)
121. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci. 2000;20(13):5115-23. (Pubitemid 30421714)
122. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM,et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci. 2007;27(16):4424-34. (Pubitemid 46640726)
123. Usdin MT, Shelbourne PF, Myers RM, Madison DV. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet. 1999;8(5): 839-46. (Pubitemid 29189051)
124. Gibson HE, Reim K, Brose N, Morton AJ, Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur J Neurosci. 2005;22(7):1701-12. (Pubitemid 41482958)
125. Milnerwood AJ, Cummings DM, Dallerac GM, Brown JY, Vatsavayai SC, Hirst MC, et al. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet. 2006;15(10):1690-703. (Pubitemid 43904835)
126. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23(1):181-92. (Pubitemid 29262475)
127. Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain. 2004;127(Pt 3):505-16. (Pubitemid 38295468)
128. Torres-Peraza JF, Giralt A, Garcia-Martinez JM, Pedrosa E, Canals JM, Alberch J. Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol Dis. 2008;29(3):409-21.
129. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad SciUSA. 1999;96(15):8727-32. (Pubitemid 29354859)
130. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 2001;14(9):1492-504. (Pubitemid 35463716)
131. Collingridge GL, Kehl SJ, McLennan H. The antagonism of amino acid-induced excitations of rat hippocampal CA1 neurones in vitro. J Physiol. 1983;334:19-31. (Pubitemid 13176080)
132. Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A. 2009;106(12):4906-11.
133. Jay TM. Dopamine: A potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol. 2003;69(6):375-90. (Pubitemid 36859925)
134. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol. 1997;42(2):215-21. (Pubitemid 27340467)
135. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006;15(6):965-77. (Pubitemid 43338237)
136. van Oostrom JC, Maguire RP,Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65(6):941-3. (Pubitemid 41362149)
137. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996;40(1):49-54. (Pubitemid 26250142)
138. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A. 1998;95(11):6480-5. (Pubitemid 28249039)
139. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem. 2006;96(3):743-57.
140. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000;9(9):1259-71. (Pubitemid 30312475)
141. Elias GM, Funke L, Stein V, Grant SG, Bredt DS, Nicoll RA. Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins. Neuron. 2006;52(2):307-20. (Pubitemid 44548345)
142. Funke L, Dakoji S, Bredt DS. Membrane-associated guanylate kinases regulate adhesion and plasticity at cell junctions. Annu Rev Biochem. 2005;74:219-45. (Pubitemid 40995507)
143. XuW. PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity. Curr Opin Neurobiol. 2011;21(2):306-12.
144. Kim E, Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci. 2004;5(10):771-81. (Pubitemid 39336214)
145. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci. 2001;24:1-29. (Pubitemid 32695221)
146. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamineexpanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001;276(27):24713-8.
147. Rizo J, Sudhof TC. Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci. 2002;3(8):641-53. (Pubitemid 135706672)
148. Edwardson JM, Wang CT, Gong B, Wyttenbach A, Bai J, Jackson MB, et al. Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J Biol Chem. 2003;278(33):30849-53. (Pubitemid 36994594)
149. Morton AJ, Edwardson JM. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem. 2001;76(1):166-72. (Pubitemid 32044379)
150. Morton AJ, Faull RL, Edwardson JM. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res Bull. 2001;56(2):111-7. (Pubitemid 33026453)
151. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004;33(5):517-33. (Pubitemid 40768575)
152. Glynn D, Bortnick RA, Morton AJ. Complexin II is essential for normal neurological function in mice. Hum Mol Genet. 2003;12(19):2431-48. (Pubitemid 37220408)
153. Wasiak S, Quinn CC, Ritter B, de HE, Baranes D, Plomann M, et al. The Ras/Rac guanine nucleotide exchange factor mammalian Son-of-sevenless interacts with PACSIN 1/syndapin I, a regulator of endocytosis and the actin cytoskeleton. J Biol Chem. 2001;276(28):26622-8.
154. Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet. 2002;11(21):2547-58. (Pubitemid 35174685)
155. Cunha C, Brambilla R, Thomas KL. Asimple role forBDNF in learning and memory? Front Mol Neurosci. 2010;3:1.
156. del Toro D, Canals JM, Gines S,Kojima M, Egea G, Alberch J. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci. 2006;26(49):12748-57. (Pubitemid 44904570)
157. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127-38. (Pubitemid 38902819)
158. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493-8. (Pubitemid 32679077)
159. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007;81(5-6):294-330. (Pubitemid 46528643)
160. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5(6):311-22.
161. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389(6653):856-60. (Pubitemid 27462980)
162. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250-8. (Pubitemid 38620801)
163. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem. 2000;75(5):2190-9.
164. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brainderived neurotrophic factor in Huntington disease. Brain Res. 2000;866(1-2):257-61. (Pubitemid 30313028)
165. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B. Brainderived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008;105(2):369-79. (Pubitemid 351490006)
166. Xie Y, Hayden MR,XuB. BDNFoverexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708- 18.
167. Gines S, Bosch M, Marco S, Gavalda N, Diaz-Hernandez M, Lucas JJ, et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci. 2006;23(3):649-58.
168. Gines S, Paoletti P, Alberch J. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J Biol Chem. 2010;285(28):21537-48.
169. Lu Y, Christian K, Lu B. BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008;89(3):312-23. (Pubitemid 351318269)
170. Jia Y, Gall CM, Lynch G. Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum. J Neurosci. 2010;30(43):14440-5.
171. Picconi B, Passino E, Sgobio C, Bonsi P, Barone I, Ghiglieri V, et al. Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiol Dis. 2006;22(1):143-52.
172. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004;24(35): 7727-39. (Pubitemid 39186828)
173. Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, et al. Diminished activity-dependent brainderived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther. 2010;335(1):13-22.
174. Simmons DA, Mehta RA, Lauterborn JC, Gall CM, Lynch G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol Dis. 2011;41(2):436-44.
175. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545-64. (Pubitemid 44450210)
176. Saavedra A, Garcia-Martinez JM, Xifro X, Giralt A, Torres-Peraza JF, Canals JM, et al. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ. 2010;17(2):324-35.
177. Saavedra A, Giralt A, Rue L, Xifro X, Xu J, Ortega Z, et al. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: A STEP in the resistance to excitotoxicity. J Neurosci. 2011;31(22):8150-62.
178. Ernfors P, Bramham CR. The coupling of a trkB tyrosine residue to LTP. Trends Neurosci. 2003;26(4):171-3. (Pubitemid 36411995)
179. Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci. 2009;10(12):850-60.
180. Kennedy MB,Beale HC, Carlisle HJ,Washburn LR. Integration of biochemical signalling in spines. Nat Rev Neurosci. 2005;6(6):423-34. (Pubitemid 40774860)
181. Mansuy IM, Shenolikar S. Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. Trends Neurosci. 2006;29(12):679-86. (Pubitemid 44794536)
182. Mayford M. Protein kinase signaling in synaptic plasticity and memory. Curr Opin Neurobiol. 2007;17(3):313-7. (Pubitemid 46880332)
183. Saavedra A, Alberch J, Perez-Navarro E. Don't Take Away My P: Phosphatases as Therapeutic Targets in Huntington's Disease. Huntington's Disease-Core Concepts and Current Advances, 465-494. 2012. InTech. Ref Type: Generic.
184. Xifro X, Giralt A, Saavedra A, Garcia-Martinez JM, Diaz-Hernandez M, Lucas JJ, et al. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity. Neurobiol Dis. 2009;36(3):461-9.
185. Malleret G, Haditsch U, Genoux D, Jones MW, Bliss TV, Vanhoose AM, et al. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell. 2001;104(5):675-86. (Pubitemid 32241018)
186. Mansuy IM, Mayford M, Jacob B, Kandel ER, Bach ME. Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to longterm memory. Cell. 1998;92(1):39-49. (Pubitemid 28053296)
187. Monti B, Berteotti C, Contestabile A. Dysregulation of memory-related proteins in the hippocampus of aged rats and their relation with cognitive impairment. Hippocampus. 2005;15(8):1041-9. (Pubitemid 43056992)
188. Riedel G. If phosphatases go up, memory goes down. Cell Mol Life Sci. 1999;55(4):549-53. (Pubitemid 29221589)
189. Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa T, et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell. 2001;107(5):617-29. (Pubitemid 34014863)
190. Goto S, Matsukado Y, Miyamoto E, Yamada M. Morphological characterization of the rat striatal neurons expressing calcineurin immunoreactivity. Neuroscience. 1987;22(1):189-201. (Pubitemid 17106767)
191. Hernandez-Espinosa D, Morton AJ. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Res Bull. 2006;69(6):669-79. (Pubitemid 43728746)
192. Lievens JC, Woodman B, Mahal A, Bates GP. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci. 2002;20(4):638-48.
193. Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, et al. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci. 2010;30(43):14318-29.
194. Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain. 2009;2:33.
195. Shimizu K, Okada M, Nagai K, Fukada Y. Suprachiasmatic nucleus circadian oscillatory protein, a novel binding partner of K-Ras in the membrane rafts, negatively regulatesMAPK pathway. J Biol Chem. 2003;278(17):14920-5. (Pubitemid 36799821)
196. Shimizu K, Phan T, Mansuy IM, Storm DR. Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell. 2007;128(6):1219-29. (Pubitemid 46427874)
197. Fitzpatrick CJ, Lombroso PJ. The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. Front Neuroanat. 2011;5:47.
198. Lombroso PJ, Murdoch G, Lerner M. Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum. Proc Natl Acad Sci U S A. 1991;88(16):7242-6. (Pubitemid 21915126)
199. Boulanger LM, Lombroso PJ, Raghunathan A, During MJ, Wahle P, Naegele JR. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J Neurosci. 1995;15(2):1532-44.
200. Braithwaite SP, Paul S, Nairn AC, Lombroso PJ. Synaptic plasticity: One STEP at a time. Trends Neurosci. 2006;29(8):452-8. (Pubitemid 44118442)
201. Li S, Tian X, Hartley DM, Feig LA. Distinct roles for Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and Ras-GRF2 in the induction of long-term potentiation and long-term depression. J Neurosci. 2006;26(6):1721-9. (Pubitemid 43236984)
202. Abel T, Nguyen PV. Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog Brain Res. 2008;169:97-115. (Pubitemid 351454062)
203. Ariano MA, Aronin N, DiFiglia M, Tagle DA, Sibley DR, Leavitt BR, et al. Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res. 2002;68(6):716-29. (Pubitemid 34594988)
204. Ariano MA,Wagle N, Grissell AE. Neuronal vulnerability in mouse models of Huntington's disease: Membrane channel protein changes. J Neurosci Res. 2005;80(5):634-45. (Pubitemid 40896184)
205. Colbran RJ, Brown AM. Calcium/calmodulin-dependent protein kinase II and synaptic plasticity. Curr Opin Neurobiol. 2004;14(3):318-27. (Pubitemid 38759862)
206. Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci. 2002;3(3):175-90. (Pubitemid 135706588)
207. Deckel AW, Gordinier A, Nuttal D, Tang V, Kuwada C, Freitas R, et al. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: Effects of L-NAME on symptom progression. Brain Res. 2001;6;919(1):70-81. (Pubitemid 33016591)
208. Deckel AW, Elder R, Fuhrer G. Biphasic developmental changes in Ca2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice. Neuroreport. 2002;13(5):707-11. (Pubitemid 34293496)
209. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004;20(3):146-54.
210. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003;19(5):233-8. (Pubitemid 36511427)
211. Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: Promises, pitfalls and prospects. Expert Opin Ther Targets. 2003;7(1):101-14. (Pubitemid 36204592)
212. Kandel ER. The molecular biology of memory storage: A dialog between genes and synapses. Biosci Rep. 2001;21(5):565-611. (Pubitemid 34816190)
213. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 1994;79(1):59-68.
214. Won J, Silva AJ. Molecular and cellular mechanisms of memory allocation in neuronetworks. Neurobiol Learn Mem. 2008;89(3):285-92. (Pubitemid 351318270)
215. Altarejos JY, Montminy M. CREB and the CRTC coactivators: Sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3):141-51.
216. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35(4):605-23. (Pubitemid 35229980)
217. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591-601.
218. Sadri-Vakili G, Cha JH. Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol. 2006;2(6):330-8. (Pubitemid 43811543)
219. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/-mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron. 2004;42(6):947-59. (Pubitemid 38798233)
220. Oliveira AM, Abel T, Brindle PK, Wood MA. Differential role for CBP and p300 CREB-binding domain in motor skill learning. Behav Neurosci. 2006;120(3):724-9. (Pubitemid 44050552)
221. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87(5):953-9. (Pubitemid 26404293)
222. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003;100(4):2041-6. (Pubitemid 36254570)
223. Fellin T. Communication between neurons and astrocytes: Relevance to the modulation of synaptic and network activity. J Neurochem. 2009;108(3):533-44.
224. Haydon PG. GLIA: Listening and talking to the synapse. Nat Rev Neurosci. 2001;2(3):185-93. (Pubitemid 33673371)
225. Santello M, Volterra A. Neuroscience: Astrocytes as aidememoires. Nature. 2010;463(7278):169-70.
226. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144(5):810-23.
227. Schummers J, Yu H, Sur M. Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. Science 2008;320(5883):1638-43. (Pubitemid 351931254)
228. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 2005;171(6):1001-12.
229. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A. 2009;106(52):22480-5.
230. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem. 2010;285(14):10653-61.
231. Faideau M, Kim J, Cormier K, Gilmore R,Welch M, Auregan G, et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington's disease subjects. Hum Mol Genet. 2010;19(15):3053-67.
232. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci. 2008;28(13):3277-90. (Pubitemid 351469331)
233. Wang DD, Bordey A. The astrocyte odyssey. Prog Neurobiol. 2008;86(4):342-67.
234. Harris GJ, Codori AM,Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in presymptomatic, gene-tested persons at-risk for Huntington's disease. Brain. 1999;122 (Pt 9):1667-78. (Pubitemid 29425670)
235. Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Landwehrmeyer GB, et al. Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Exp Neurol. 2011;231(2):214-22.
236. Sturrock A, Leavitt BR. The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol. 2010;23(4):243-59.
237. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord. 2012;27(1):31-41.
238. Cubo E, Shannon KM,TracyD, Jaglin JA, Bernard BA,Wuu J, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268-71. (Pubitemid 44563842)
239. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000;15(1):173-6 (Pubitemid 30038010)
240. de Tommaso M. , Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 2004;19(12):1516-8. (Pubitemid 40109484)
241. de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43-6. (Pubitemid 46204317)
242. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol. 2002;9(6):689-90.
243. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, et al. A randomized, placebocontrolled trial of latrepirdine in Huntington disease. Arch Neurol. 2010;67(2):154-60.
244. Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10(2):126-40.
245. Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116(5):1410-24.
246. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, et al. CEP-1347 reduces mutant huntingtinassociated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008;39(1):8-20.
247. DuanW, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis. 2008;30(3):312-22.
248. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. The antidepressant sertraline improves the pheno type, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol. 2008;210(1):154-63.
249. DeMarch Z, Giampa C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis. 2008;30(3):375-87.
250. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One. 2010;5(10):e13417.
251. Nithianantharajah J, Hannan AJ. Mechanisms mediating brain and cognitive reserve: Experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):331-9.
252. Spires TL, Grote HE, Varshney NK, Cordery PM, van DA, Blakemore C, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci. 2004;24(9):2270-6. (Pubitemid 38314558)
253. Zajac MS, Pang TY, Wong N, Weinrich B, Leang LS, Craig JM, et al. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus. 2010;20(5):621-36.
254. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A. 2003;100(5):2911-6. (Pubitemid 36297597)
255. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011;95(3):373-95.
256. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med. 2012;18(1):153-8.
257. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2012;18(1):159-65.
258. Cayzac S, Delcasso S, Paz V, Jeantet Y, Cho YH. Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease. Proc Natl Acad Sci U S A. 2011;108(22):9280-5.
259. Pallier PN, Drew CJ, Morton AJ. The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task-and protocol-dependent: Influence of non-motor factors on locomotor function. Brain Res Bull. 2009;78(6):347-55.
260. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 1999;19(8):3248-57. (Pubitemid 29174016)
261. Fine EM, Delis DC, Wetter SR, Jacobson MW, Hamilton JM, Peavy G, et al. Identifying the "source" of recognition memory deficits in patients with Huntington's disease or Alzheimer's disease: Evidence from the CVLT-II. J Clin Exp Neuropsychol. 2008;30(4):463-70. (Pubitemid 351563083)
262. Marcora E, Kennedy MB. The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-kappaB from the synapse to the nucleus. Hum Mol Genet. 2010;19(22):4373-84.